Compare R & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | R | ERAS |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Rental/Leasing Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.5B |
| IPO Year | 1994 | 2021 |
| Metric | R | ERAS |
|---|---|---|
| Price | $219.83 | $17.86 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 12 |
| Target Price | ★ $213.78 | $12.08 |
| AVG Volume (30 Days) | 244.4K | ★ 5.0M |
| Earning Date | 04-23-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.65% | N/A |
| EPS Growth | 7.96 | ★ 36.23 |
| EPS | ★ 11.94 | N/A |
| Revenue | ★ $12,665,000,000.00 | N/A |
| Revenue This Year | $3.91 | N/A |
| Revenue Next Year | $5.74 | N/A |
| P/E Ratio | $18.47 | ★ N/A |
| Revenue Growth | ★ 0.23 | N/A |
| 52 Week Low | $130.16 | $1.06 |
| 52 Week High | $230.39 | $18.20 |
| Indicator | R | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 65.33 | 63.75 |
| Support Level | $184.78 | $1.72 |
| Resistance Level | $229.19 | $18.20 |
| Average True Range (ATR) | 5.55 | 1.30 |
| MACD | 2.52 | 0.01 |
| Stochastic Oscillator | 89.35 | 88.45 |
Ryder System Inc operates in three business segments: (1) Fleet Management Solutions which provides full-service leasing and leasing with flexible maintenance options, commercial rental and maintenance services of trucks, tractors and trailers to customers; (2) Supply Chain Solutions (SCS), which provides integrated logistics solutions, including distribution management, dedicated transportation, transportation management, brokerage, e-commerce, last mile, and professional services; and (3) Dedicated Transportation Solutions (DTS), which provides turnkey transportation solutions in the U.S., including dedicated vehicles, professional drivers, management, and administrative support.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.